Cargando…

Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells

BACKGROUND: Most patients with advanced Ewing's sarcoma (EWS) respond poorly to conventional chemotherapy, indicating the need for new treatment approaches. Epigenetic events, such as promoter hypermethylation and chromatin histone deacetylation, silence the expression of tumor suppressor genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurtubise, Annie, Bernstein, Mark L, Momparler, Richard L
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600626/ https://www.ncbi.nlm.nih.gov/pubmed/19014694 http://dx.doi.org/10.1186/1475-2867-8-16

Ejemplares similares

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
por: Lemaire, Maryse, et al.
Publicado: (2008)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
por: Momparler, Richard L., et al.
Publicado: (2021)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
por: Karahoca, Metin, et al.
Publicado: (2013)

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma
por: Hassler, Melanie R., et al.
Publicado: (2012)

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1
por: Bouchat, Sophie, et al.
Publicado: (2015)

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
por: Cortvrindt, R., et al.
Publicado: (1987)

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2021)

Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2022)

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
por: Andersson, Mattias K, et al.
Publicado: (2008)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines
por: de Andrade, Pamela Viani, et al.
Publicado: (2016)

Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
por: Chiang, Tung-chin, et al.
Publicado: (2019)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
por: Weberpals, Johanne I, et al.
Publicado: (2011)

miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor
por: Iida, Keiichiro, et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

MicroRNA-181c prevents apoptosis by targeting of FAS receptor in Ewing’s sarcoma cells
por: Kawano, Masanori, et al.
Publicado: (2018)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
por: Tsai, Chiou-Tsun, et al.
Publicado: (2013)

5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
por: Patra, Aditi, et al.
Publicado: (2011)

Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
por: Tomita, Tatsunosuke, et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
por: Di Martile, Marta, et al.
Publicado: (2018)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
por: Berghuis, Dagmar, et al.
Publicado: (2012)

Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
por: St Germain, Carly, et al.
Publicado: (2010)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
por: Maslov, Alexander Y., et al.
Publicado: (2012)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
por: Ding, Xiao-Lei, et al.
Publicado: (2016)

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines
por: Welch, Darcy, et al.
Publicado: (2019)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988)

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_675rtedlid5b0fu6pkm19ceg1m